Alteration of the development of mammary hyperplastic alveolar nodules and uterine adenomyosis in SHN mice by different schedules of treatment with CB-154

Taketoshi Mori, T Mori, H Nagasawa
Acta endocrinologica · 1984 · vol. 107(2) , pp. 245–249 · doi:10.1530/acta.0.1070245 · PMID:6495991 · W2038603240
article OA: closed CC0 ⤵ 9 in-corpus citations
View on OpenAlex View on PubMed View at publisher

Abstract

The effect of different schedules of bromocriptine-mesilate (CB-154; 0.2 mg/day) treatment on the development of precancerous mammary hyperplastic alveolar nodules (HAN) and uterine adenomyosis was investigated in a virgin SHN strain of mice. CB-154 treatment for 7 weeks beginning at 4 weeks of age enhanced the development of HAN at an advanced age, the shorter period of treatment having no effect. In contrast, spontaneous development of adenomyosis was markedly inhibited in mice treated with CB-154 for more than 4 weeks beginning at 4 weeks of age, but not for less than 3 weeks of the treatment. The inhibitory effect of CB-154 was not counteracted by pituitary grafting. Furthermore, CB-154 treatment between 11 and 18 weeks of age also accelerated HAN formation, but had no effect on the development of adenomyosis. These results indicate that in mice a certain period of CB-154 treatment is necessary to produce changes in the development of HAN and adenomyosis, and that the inhibitory effect of CB-154 on the development of adenomyosis is age-dependent. The different response between mammary gland cells and uterine cells to CB-154 exposure is discussed with special reference to cell proliferation.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Breast Breast Neoplasms Bromocriptine Endometriosis Precancerous Conditions Uterine Neoplasms Uterus Age Factors Animals Breast Breast Breast Neoplasms Bromocriptine Dose-Response Relationship, Drug Endometriosis Female Hyperplasia Mice Mice, Inbred Strains Precancerous Conditions

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (9)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:50.790931+00:00
License: CC0 · commercial use OK